Author

Demi Niforos

Observed names: D. Niforos, Demi A. Niforos

Observed institutions: Newland Medical Associates, Arbutus Biopharma (Canada), Gilead Sciences (United States)

OpenAlex ID: A5072776178

A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients

2010 · MacDonald, Mark Kowalski, et al. · Drug Design Development and Therapy · 74

A phase I/II study of TKM-080301, a PLK1-targeted RNAi in patients with adrenocortical cancer (ACC).

2016 · Michael J Demeure, Tannaz Armaghany, et al. · Journal of Clinical Oncology · 49

Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis

2013 · Animesh Pardanani, Jason Gotlib, et al. · Blood · 45

A phase 2a study evaluating the multi-dose activity of ARB-1467 in HBeAg positive and negative virally suppressed subjects with hepatitis B

2017 · A. Streinu-Cercel, E. Gane, et al. · Journal of Hepatology · 34

Results of a first-in-human phase I study of SRF231, a fully human, high-affinity anti-CD47 antibody.

2020 · Amita Patnaik, Anna Spreafico, et al. · Journal of Clinical Oncology · 28

A phase III randomized controlled study comparing iron sucrose intravenously (IV) to no iron treatment of anemia in cancer patients undergoing chemotherapy and erythropoietin stimulating agent (ESA) therapy

2007 · R. E. Bellet, H. Ghazal, et al. · Journal of Clinical Oncology · 21

IV iron sucrose for cancer and/or chemotherapy-induced anemia in patients treated with erythropoiesis-stimulating agents

2011 · Lowell B. Anthony, Nashat Y. Gabrail, et al. · Community Oncology · 13

Dose-Response Analyses Of Momelotinib (CYT387), a JAK1 and JAK2 Inhibitor, From a Phase I/II Study (CCL09101) In Treatment Of Myelofibrosis

2013 · Yan Xin, Lixin Shao, et al. · Blood · 5

An open-label, multi-center, phase I/II, dose escalation study of IV TKM-080301 in subjects with advanced hepatocellular carcinoma

2016 · G.K. Abou-Alfa, J.H. Yoon, et al. · European Journal of Cancer · 4

921 Level of Expression of Epcam and Response to Vicinium™ in Non Muscle-invasive Transitional Cell Carcinoma of the Bladder

2010 · M.M. Kowalski, N. Jones, et al. · European Urology Supplements

MP-20.09: Frequency and Level of Expression of Epcam in Non Muscle-Invasive Transitional Cell Carcinoma of the Bladder

2009 · M. Kowalski, N. Jones, et al. · Urology

Works count: 12

Citation count: 273

H-index: 7

I10-index: 7